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a uremic patient receiving hemodialysisTo the Editor,
Shewanella putrefaciens is rarely responsible for clinical
syndromes or bacteremia,1,2 but it is a potential pathogen
for patients with immunocompromised conditions.1,3
Recently Wu et al4 reported that a comparison between
patients under hemodialysis with community-onset
bacteremia caused by community- and health care-
associated methicillin-resistant Staphylococcus aureus
strains. Despite Staphylococcus spp. being the most com-
mon pathogen of catheter-related bacteremia in patients
receiving hemodialysis for end-stage renal disease,4 the
nonfermentative Gram-negative bacilli also play an impor-
tant role. Here, we are reporting a uremic patient who was
diagnosed as S. putrefaciens bacteremia associated with
permanent catheter-related bloodstream infection.
An 82-year-old woman was admitted to the ward with
fever and chills for 2 days. The patient had a history of
chronic renal failure undergoing regular hemodialysis for
the past 5 years. She had cervical cancer with bladder in-
vasion, stage 4, complicating with bilateral hydronephrosis.
Initially, she was diagnosed as complicated urinary tract
infection, and the urine culture showed the growth of
Proteus mirabilis. She received cefuroxime 1 g intrave-
nously every 6 hours. Defervescence was noted and urine
analysis yielded no pyuria after she received a 7-day course
of antibiotic therapy. Unfortunately, she suffered from
fever again at the 14th admission day. The blood cultures
from both peripheral vessels and intrapermanent catheter
both yielded a Gram-negative bacillus. The isolate was
identified as S. putrefaciens by conventional method and
Phoenix NID card (Becton Dickinson Diagnostic Systems,
Sparks, MD, USA). The isolate was further analyzed by
matrix-assisted laser desorption ionization-time of flight
mass spectrometry (MALDI-TOF) using Bruker Biotyper
(Bruker Daltonik GmbH, Bremen, Germany) and identified
as S. putrefaciens (score value, 2.249; Fig. 1).2http://dx.doi.org/10.1016/j.jmii.2014.01.010
1684-1182/Copyright ª 2014, Taiwan Society of Microbiology. Published
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/Minimum inhibitory concentrations (MICs) of the isolates
to antimicrobial agents were determined using the E-test
(AB Biodisk, Solna, Sweden) according to the manufac-
turer’s guidelines. The isolate was resistant to cefazolin
(MIC, 64 mg/L), cefmetazole (64 mg/L), ciprofloxacin
(8 mg/L), and imipenem (4 mg/L), and susceptible to
cefotaxime (0.5 mg/L), doripenem (0.25 mg/L), mer-
openem (0.5 mg/L), and amikacin (8 mg/L). The patient
received doripenem 500 mg intravenously every 24 hours,
supplemented with 500 mg intravenously after hemodialy-
sis. The patient was discharged home after a complete 14-
day therapy of doripenem.
S. putrefaciens is a nonfermentative Gram-negative
facultative rod that produces hydrogen sulfide and re-
duces iron metabolically.1,3,4 It is a ubiquitous saprophyte
and can be isolated from the marine environment,
contaminated water, and food.1,3 S. putrefaciens was
initially classified as a Pseudomonas sp., and it has
become a pathogen for clinical infections in recent
years.1,3,5,6 S. putrefaciens is often resistant to peni-
cillin, and first- and second-generation cephalosporins,
but susceptible to 3rd- and 4th-generation cephalospo-
rins, carbapenem, and aminoglycosides. The risk factors
of S. putrefaciens infections include malignancy, chronic
renal failure, and immunosuppressed patients.1,3e5 The
clinical outcome is often benign, except in rare uremic
patients,1,5,6 which may be due to immunologic dysregu-
lations, poor nutrition, iron overload, or hemodialysis.
Our patient also had a permanent catheter in situ for
hemodialysis, which was associated with bloodstream
infection. Liu et al6 reported that the increasing
catheter-related infection rate was associated with a
poor compliance of the care bundle, because most cases
were due to inadequate barrier precautions and inap-
propriate hand hygiene.6
Clinicians should perform bundle-care for decreasing
catheter-related infection, and be aware that S. putrefaciensby Elsevier Taiwan LLC. This is an open access article under the CC
).
Figure 1. Spectra generated by MALDI-TOF Bruker Biotyper for Shewanella putrefaciens. The absolute intensities of the ions are
shown on the y axis and the mass-to-charge ratios (m/z) of the ions are shown on the x axis. MALDI-TOF Z matrix-assisted laser
desorption ionization-time of flight mass spectrometry.
160 Correspondencecan probably be regarded as an emerging opportunistic path-
ogen in patients receiving hemodialysis.
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